Wentao Wu
Direttore operativo presso Xynomic Pharmaceuticals, Inc.
Profilo
Wentao Wu is currently the Chief Operating Officer at Xynomic Pharmaceuticals, Inc. She previously worked as the Director of Business Development at Hutchison MediPharma Ltd.
from 2002 to 2004, and as the Head of Research and Development at American Oriental Bioengineering, Inc. from 2004 to 2009.
She also served as the Chief Operating Officer at Xynomic Pharmaceuticals Holdings, Inc. Dr. Wu holds a Master's in Business Administration from Indiana University and a doctorate from Purdue University.
Posizioni attive di Wentao Wu
| Società | Posizione | Inizio |
|---|---|---|
Xynomic Pharmaceuticals, Inc.
 Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Direttore operativo | - |
Precedenti posizioni note di Wentao Wu
| Società | Posizione | Fine |
|---|---|---|
| AMERICAN ORIENTAL BIOENGINEERING, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2009 |
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01/01/2004 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Direttore operativo | - |
Formazione di Wentao Wu
| Indiana University | Masters Business Admin |
| Purdue University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AMERICAN ORIENTAL BIOENGINEERING, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Health Technology |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
- Borsa valori
- Insiders
- Wentao Wu
